Invivyd (IVVD) Price & Analysis

Compare

599 Followers

IVVD Stock Chart & Stats

$1.75

-$0.05(-9.00%)

At close: Jan 08 4:00 PM EST

$1.75

-$0.05(-9.00%)

Day’s Range― - ―

52-Week Range$0.35 - $2.74

Previous CloseN/A

Volume606.77K

Average Volume (3M)5.22M

Market Cap

$375.22M

Enterprise Value$53.87M

Total Cash (Recent Filing)$34.91M

Total Debt (Recent Filing)$2.96M

Price to Earnings (P/E)―

Beta1.63

Next Earnings

Nov 12, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding214,409,450

10 Day Avg. Volume9,066,011

30 Day Avg. Volume5,215,940

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.14

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit1.25

Enterprise Value/Ebitda-0.49

Forecast

1Y Price Target

$7.50

Price Target Upside328.57% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial StrengthA $57.5 million equity raise enhances Invivyd's runway to launch VYD2311 and advance its pipeline.

Product EfficacyVYD2311 maintains ~17-fold improved potency versus PEMGARDA across dominant variants, supporting a broad prevention and treatment profile.

Regulatory AdvancementsRegulatory clarity achieved with alignment on a single, randomized, placebo-controlled prevention trial for VYD2311, supporting a potential Biologics License Application.

Bears Say

Market CompetitionCommercial PEMGARDA uptake provides a bridge into respiratory season, with limited CMC spend for VYD2311 and disciplined operating expenses.

Policy UncertaintyEmerging policy discussions suggest potential U.S. vaccine access changes that could favor long-acting prophylactic antibodies.

Invivyd News

Invivyd announces IND clearance, alignment with FDA on VYD2311 program

Invivyd (IVVD) announced that the FDA has cleared the company’s Investigational New Drug application and provided feedback to...

12d ago

IVVD

Invivyd initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Invivyd (IVVD) with an Overweight rating and $10 price target Published first on...

12d ago

IVVD

Invivyd files $350M mixed securities shelf

16:19 EDT Invivyd (IVVD) files $350M mixed securities shelf Published first on TheFly – the ultimate source for...

15d ago

IVVD

Invivyd appoints Wave Life Sciences CEO Paul Bolno to board

Invivyd (IVVD) announced the appointment of Paul Bolno to its board of directors and as a member of...

23d ago

WVE

IVVD

Invivyd’s VYD2311 Receives FDA Clearance for Trials

Invivyd ( ($IVVD) ) has shared an update. On October 6, 2025, Invivyd, Inc. announced that the U.S....

12d ago

IVVD

Invivyd Appoints New Director Amid Nasdaq Compliance

Invivyd ( ($IVVD) ) has shared an update. On September 22, 2025, Invivyd, Inc. appointed Paul B. Bolno,...

23d ago

IVVD

Invivyd announces appointment of Kuhl as Chief Communications Officer

Invivyd (IVVD) announced the appointment of Kristie Kuhl as Chief Communications Officer. Kuhl will lead the Company’s communications...

1M ago

IVVD

Invivyd’s Strategic Growth and Diversification: Analyst Recommends Buy Rating

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Invivyd, with a...

1M ago

IVVD

Invivyd announces SPEAR Study Group recommended Long COVID study design

Invivyd (IVVD) announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design...

1M ago

IVVD

Invivyd’s Promising Position in the Antibody Market: Buy Rating Supported by Strong Data and Financial Growth

Invivyd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C....

2M ago

IVVD

Invivyd Raises $53.5 Million in Public Offering

Invivyd ( ($IVVD) ) has shared an update. On August 20, 2025, Invivyd, Inc. entered into an underwriting...

2M ago

IVVD

Invivyd 50M share Spot Secondary priced at 52c

Cantor Fitzgerald acted as sole book running manager for the offering. Published first on TheFly – the ultimate...

2M ago

IVVD

Invivyd Reports Strong Revenue Growth Amid Strategic Advances

Invivyd ( ($IVVD) ) has released its Q2 earnings. Here is a breakdown of the information Invivyd presented...

2M ago

IVVD

Closing Bell Movers: Nordson up 5% after Q3 earnings beat

In the opening hour of the evening session, U.S. equity futures are little changed following more losses in...

2M ago

IVVD FAQ

What was Invivyd’s price range in the past 12 months?

Invivyd lowest stock price was $0.35 and its highest was $2.74 in the past 12 months.

What is Invivyd’s market cap?

Invivyd’s market cap is $375.22M.

When is Invivyd’s upcoming earnings report date?

Invivyd’s upcoming earnings report date is Nov 12, 2025 which is in 25 days.

How were Invivyd’s earnings last quarter?

Invivyd released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.116.

Is Invivyd overvalued?

According to Wall Street analysts Invivyd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Invivyd pay dividends?

Invivyd does not currently pay dividends.

What is Invivyd’s EPS estimate?

Invivyd’s EPS estimate is -0.09.

How many shares outstanding does Invivyd have?

Invivyd has 214,409,450 shares outstanding.

What happened to Invivyd’s price movement after its last earnings report?

Invivyd reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went down -11.25%.

Which hedge fund is a major shareholder of Invivyd?

Currently, no hedge funds are holding shares in IVVD

Invivyd Stock Smart Score

Outperform

Fundamentals

Return on Equity

-120.08%

Trailing 12-Months

Asset Growth

-49.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Invivyd

Invivyd, Inc. (IVVD) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases. The company's core products include monoclonal antibodies designed to treat and prevent viral infections, with a particular emphasis on addressing unmet medical needs in the field of infectious disease prevention and treatment.

Invivyd (IVVD) Earnings & Revenues

Historic Earnings Reports

IVVD Stock 12 Month Forecast

Average Price Target

$7.50

▲(328.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.8953846153846152,2.5707692307692307,3.246153846153846,3.9215384615384616,4.596923076923077,5.272307692307692,5.947692307692307,6.623076923076923,7.298461538461538,7.973846153846154,8.649230769230769,9.324615384615385,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.7030769230769232,2.186153846153846,2.6692307692307695,3.1523076923076925,3.6353846153846154,4.118461538461538,4.601538461538461,5.084615384615384,5.567692307692307,6.05076923076923,6.533846153846153,7.016923076923077,{"y":7.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.22,1.5107692307692306,1.8015384615384615,2.0923076923076924,2.3830769230769233,2.6738461538461538,2.9646153846153847,3.2553846153846155,3.546153846153846,3.8369230769230773,4.127692307692308,4.418461538461538,4.7092307692307696,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >